Journal
JOURNAL OF PSYCHOPHARMACOLOGY
Volume 24, Issue 3, Pages 363-371Publisher
SAGE PUBLICATIONS LTD
DOI: 10.1177/0269881108096509
Keywords
AVE1625; CB1 antagonist; cannabis; cannabinoid; healthy volunteers; human; pharmacodynamics; volcano (R) vaporiser; THC
Ask authors/readers for more resources
CB1 antagonists such as AVE1625 are potentially useful in the treatment of obesity, smoking cessation and cognitive impairment. Proof of pharmacological action of AVE1625 in the brain can be given by antagonising the effects of delta-9-tetrahydrocannabinol (THC), a CB1/CB2 agonist. Inhibition of THC-induced effects by AVE1625 was observed on Visual Analogue Scales 'alertness', 'feeling high', 'external perception', 'body sway' and 'heart rate'. Even the lowest dose of AVE1625 20 mg inhibited most of THC-induced effects. AVE1625 did not have any effect on psychological and behavioural parameters or heart rate by itself. After THC and AVE1625 administration, changes on electroencephalography were observed. This study shows a useful method for studying the effects of CB1 antagonists. AVE1625 penetrates the brain and antagonises THC-induced effects with doses at or above 20 mg.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available